Autopsy report · NCT06873789

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

“This was a strategic business decision. There were no safety concerns contributing to this decision.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 1 year 1 month before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Incyte Corporation

Sponsor type

Industry

Conditions

Solid Tumors; Advanced Solid Tumors; Metastatic Solid Tumors

Interventions

INCB177054; Retifanlimab

Participants

9

Sites

9

Countries

United States

Trials that died the same way

• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
  “Company decision not related to any safety concerns.” (80% match in meaning)
• MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
  “Business Decision; No Safety Or Efficacy Concerns.” (79% match in meaning)
• A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
  “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.” (77% match in meaning)
• A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
  “Sponsor's decision, no safety concerns.” (73% match in meaning)
• EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension
  “There were no safety or effectiveness concerns. There were concerns about completing enrollment due to a competitive device's potential approval.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.